[go: up one dir, main page]

DE602005027858D1 - 3-substituierte 5- und 6-aminoalkylindol-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase i - Google Patents

3-substituierte 5- und 6-aminoalkylindol-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase i

Info

Publication number
DE602005027858D1
DE602005027858D1 DE602005027858T DE602005027858T DE602005027858D1 DE 602005027858 D1 DE602005027858 D1 DE 602005027858D1 DE 602005027858 T DE602005027858 T DE 602005027858T DE 602005027858 T DE602005027858 T DE 602005027858T DE 602005027858 D1 DE602005027858 D1 DE 602005027858D1
Authority
DE
Germany
Prior art keywords
aminoalkylindol
inhibitors
substituted
casein kinase
related analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005027858T
Other languages
English (en)
Inventor
William Arthur Metz Jr
Fa-Xiang Ding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of DE602005027858D1 publication Critical patent/DE602005027858D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602005027858T 2004-08-19 2005-08-16 3-substituierte 5- und 6-aminoalkylindol-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase i Expired - Lifetime DE602005027858D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60338004P 2004-08-19 2004-08-19
PCT/US2005/029053 WO2006023467A1 (en) 2004-08-19 2005-08-16 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Iϵ

Publications (1)

Publication Number Publication Date
DE602005027858D1 true DE602005027858D1 (de) 2011-06-16

Family

ID=35311279

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005027858T Expired - Lifetime DE602005027858D1 (de) 2004-08-19 2005-08-16 3-substituierte 5- und 6-aminoalkylindol-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase i

Country Status (26)

Country Link
US (2) US7629376B2 (de)
EP (1) EP1794122B1 (de)
JP (1) JP4843608B2 (de)
KR (2) KR20070043012A (de)
CN (1) CN101006055B (de)
AR (1) AR050919A1 (de)
AT (1) ATE508112T1 (de)
AU (1) AU2005277523B2 (de)
BR (1) BRPI0514380A (de)
CA (1) CA2577667C (de)
DE (1) DE602005027858D1 (de)
GT (1) GT200500214A (de)
IL (1) IL181156A (de)
JO (1) JO2724B1 (de)
MA (1) MA28863B1 (de)
MX (1) MX2007001382A (de)
NO (1) NO20071466L (de)
NZ (1) NZ552800A (de)
PA (1) PA8642901A1 (de)
PE (1) PE20060498A1 (de)
RU (1) RU2369599C2 (de)
SV (1) SV2006002192A (de)
TW (1) TWI357897B (de)
UY (1) UY29078A1 (de)
WO (1) WO2006023467A1 (de)
ZA (1) ZA200700651B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9018238B2 (en) 2009-02-12 2015-04-28 Pharmadesign, Inc. Inhibitor of casein kinase 1δ and casein kinase 1ε
RU2011146544A (ru) * 2009-04-17 2013-05-27 Силин Фармасьютикалз, Инк. Способы лечения болезней, связанных с активностью протеинкиназы ck2
WO2014001464A1 (en) 2012-06-27 2014-01-03 4Sc Discovery Gmbh Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
US20210052597A1 (en) 2018-01-29 2021-02-25 Cadila Healthcare Limited Heterocyclic compounds useful as antibacterial agents
WO2022006377A2 (en) * 2020-07-02 2022-01-06 Mbq Pharma Heterocyclic inhibitors of rho gtpases for the treatment of disease
US12209078B2 (en) 2021-10-06 2025-01-28 Mbq Pharma Crystalline forms of carbazole inhibitors of RhoGTPase for the treatment of disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296471A (en) 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
IL146729A0 (en) * 1999-06-08 2002-07-25 Aventis Pharma Inc Screening methods for altering circadian rhythm proteins
CN1814596A (zh) * 2000-04-28 2006-08-09 阿卡蒂亚药品公司 毒蕈碱性激动剂
JP4332112B2 (ja) * 2002-08-09 2009-09-16 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
ATE428711T1 (de) * 2003-12-11 2009-05-15 Aventis Pharma Inc Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3- cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i- epsilon

Also Published As

Publication number Publication date
ATE508112T1 (de) 2011-05-15
JP4843608B2 (ja) 2011-12-21
CN101006055B (zh) 2011-06-22
PA8642901A1 (es) 2006-05-16
SV2006002192A (es) 2006-06-28
US20080027124A1 (en) 2008-01-31
TWI357897B (en) 2012-02-11
IL181156A (en) 2011-09-27
ZA200700651B (en) 2008-09-25
JO2724B1 (en) 2013-09-15
TW200621711A (en) 2006-07-01
MX2007001382A (es) 2007-04-19
EP1794122A1 (de) 2007-06-13
WO2006023467A1 (en) 2006-03-02
EP1794122B1 (de) 2011-05-04
US7923466B2 (en) 2011-04-12
US20090082340A1 (en) 2009-03-26
AU2005277523A1 (en) 2006-03-02
IL181156A0 (en) 2007-07-04
UY29078A1 (es) 2006-03-31
CA2577667A1 (en) 2006-03-02
NO20071466L (no) 2007-04-19
KR20130038409A (ko) 2013-04-17
AR050919A1 (es) 2006-12-06
RU2007109783A (ru) 2008-09-27
CA2577667C (en) 2011-01-04
GT200500214A (es) 2006-03-27
HK1105196A1 (en) 2008-02-06
NZ552800A (en) 2010-11-26
JP2008510017A (ja) 2008-04-03
RU2369599C2 (ru) 2009-10-10
KR20070043012A (ko) 2007-04-24
MA28863B1 (fr) 2007-09-03
BRPI0514380A (pt) 2008-06-10
AU2005277523B2 (en) 2011-09-29
PE20060498A1 (es) 2006-07-10
US7629376B2 (en) 2009-12-08
CN101006055A (zh) 2007-07-25

Similar Documents

Publication Publication Date Title
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
ATE374610T1 (de) 1-(2-amino-benzoyl)-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen
ATE374201T1 (de) 6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE60321324D1 (de) Sulfonylaminoderivate als neue inhibitoren von histondeacetylase
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
ATE551059T1 (de) Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
ATE428424T1 (de) 1-benzoyl-piperazin-derivate als glycin- aufnahmehemmer zur behandlung von psychosen
DE602004020793D1 (de) 5-phenyl-4-methyl-thiazol-2-yl-amin-derivate als inhibitoren von phosphatidylinositol-3-kinase-enzymen (pi3) zur behandlung entzündlicher erkrankungen der luftwege
DE60325761D1 (de) Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
DK1761520T3 (da) Kinaseinhibitorer
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
DE602004024374D1 (de) Zusammensetzungen zur verwendung als protein-kinase-inhibitoren
NL1027811A1 (nl) Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1.
EP2183254A4 (de) Inhibitoren der proteintyrosinkinaseaktivität
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DE602005022113D1 (de) Phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
DE602005006744D1 (de) Chinolinderivate zur verwendung als inhibitoren von mycobakterien
ATE412652T1 (de) Triazolopyridinylsulfanylderivate als inhibitoren der p38-map-kinase
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen